{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:44:57Z","timestamp":1788245097026,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00330-018-5729-z","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T13:09:05Z","timestamp":1537880945000},"page":"1882-1892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival"],"prefix":"10.1007","volume":"29","author":[{"given":"Steffen","family":"Marquardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha M.","family":"Kirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zeile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner","family":"Prevoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Radeleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Trillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Wiggermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank K.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"5729_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168\u20132179. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0","journal-title":"Lancet"},{"key":"5729_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL et al (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245:755\u2013762. https:\/\/doi.org\/10.1097\/01.sla.0000251366.62632.d3","journal-title":"Ann Surg"},{"key":"5729_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2016.64","volume":"114","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Palmer D et al (2016) Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 114:965\u2013971. https:\/\/doi.org\/10.1038\/bjc.2016.64","journal-title":"Br J Cancer"},{"key":"5729_CR4","doi-asserted-by":"publisher","unstructured":"Kim JH, Won HJ, Shin YM, Kim KA, Kim PN (2011) Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 196:W205\u2013W209. https:\/\/doi.org\/10.2214\/AJR.10.4937","DOI":"10.2214\/AJR.10.4937"},{"key":"5729_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1259\/bjr\/24563774","volume":"85","author":"H-X Xu","year":"2012","unstructured":"Xu H-X, Wang Y, Lu MD, Liu LN (2012) Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 85:1078\u20131084. https:\/\/doi.org\/10.1259\/bjr\/24563774","journal-title":"Br J Radiol"},{"key":"5729_CR6","doi-asserted-by":"publisher","unstructured":"Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP (2011) Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 66:322\u2013328. https:\/\/doi.org\/10.1016\/j.crad.2010.11.002","DOI":"10.1016\/j.crad.2010.11.002"},{"key":"5729_CR7","doi-asserted-by":"publisher","unstructured":"Vogl TJ, Naguib NN, Nour-Eldin NE et al (2012) Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 131:733\u2013740. https:\/\/doi.org\/10.1002\/ijc.26407","DOI":"10.1002\/ijc.26407"},{"key":"5729_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/MEG.0b013e3283502241","volume":"24","author":"JB Kuhlmann","year":"2012","unstructured":"Kuhlmann JB, Euringer W, Spangenberg HC et al (2012) Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 24:437\u2013443. https:\/\/doi.org\/10.1097\/MEG.0b013e3283502241","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5729_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","volume":"35","author":"RT Hoffmann","year":"2012","unstructured":"Hoffmann RT, Paprottka PM, Sch\u00f6n A et al (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 35:105\u2013116. https:\/\/doi.org\/10.1007\/s00270-011-0142-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5729_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","volume":"36","author":"S Rafi","year":"2013","unstructured":"Rafi S, Piduru SM, El-Rayes B et al (2013) Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 36:440\u2013448. https:\/\/doi.org\/10.1007\/s00270-012-0463-4","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5729_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M et al (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23:1309\u20131319. https:\/\/doi.org\/10.1245\/s10434-015-4968-3","journal-title":"Ann Surg Oncol"},{"key":"5729_CR12","doi-asserted-by":"publisher","unstructured":"Kirstein MM, Marquardt S, Jedicke N, et al (2017) Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol: 1\u20139. https:\/\/doi.org\/10.1007\/s00432-017-2461-z","DOI":"10.1007\/s00432-017-2461-z"},{"key":"5729_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","volume":"40","author":"TJ Vogl","year":"2017","unstructured":"Vogl TJ, Koch SA, Lotz G et al (2017) Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol 40:864\u2013872. https:\/\/doi.org\/10.1007\/s00270-017-1588-2","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5729_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"5729_CR15","doi-asserted-by":"publisher","unstructured":"Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR (2016) Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol 39:801\u2013814. https:\/\/doi.org\/10.1007\/s00270-015-1276-z","DOI":"10.1007\/s00270-015-1276-z"},{"key":"5729_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"5729_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.23781","volume":"111","author":"LM Boehm","year":"2015","unstructured":"Boehm LM, Jayakrishnan TT, Miura JT et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111:213\u2013220. https:\/\/doi.org\/10.1002\/jso.23781","journal-title":"J Surg Oncol"},{"key":"5729_CR18","doi-asserted-by":"publisher","unstructured":"Ray CE Jr, Edwards A, Smith MT et al (2013) Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 24:1218\u20131226. https:\/\/doi.org\/10.1016\/j.jvir.2013.03.019","DOI":"10.1016\/j.jvir.2013.03.019"},{"key":"5729_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1055\/s-0037-1602591","volume":"34","author":"BM Currie","year":"2017","unstructured":"Currie BM, Soulen MC (2017) Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 34:92\u2013100. https:\/\/doi.org\/10.1055\/s-0037-1602591","journal-title":"Semin Intervent Radiol"},{"key":"5729_CR20","doi-asserted-by":"publisher","unstructured":"Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS (2015) Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 41:120\u2013127. https:\/\/doi.org\/10.1016\/j.ejso.2014.09.007","DOI":"10.1016\/j.ejso.2014.09.007"},{"key":"5729_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00270-013-0826-5","volume":"37","author":"FM Moeslein","year":"2014","unstructured":"Moeslein FM, McAndrew EG, Appling WM et al (2014) Evaluation of Delcath Systems\u2019 Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Intervent Radiol 37:763\u2013769. https:\/\/doi.org\/10.1007\/s00270-013-0826-5","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5729_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/ajcp\/109.6.764","volume":"109","author":"BF Leech","year":"1998","unstructured":"Leech BF, Carter CJ (1998) Falsely elevated INR results due to the sensitivity of a thromboplastin reagent to heparin. Am J Clin Pathol 109:764\u2013768","journal-title":"Am J Clin Pathol"},{"key":"5729_CR23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/j.1875-9114.1991.tb04294.x","volume":"11","author":"NJ Schultz","year":"1991","unstructured":"Schultz NJ, Slaker RA, Rosborough TK (1991) The influence of heparin on the prothrombin time. Pharmacotherapy 11:312\u2013316","journal-title":"Pharmacotherapy"},{"key":"5729_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11894-017-0542-4","volume":"19","author":"B Doherty","year":"2017","unstructured":"Doherty B, Nambudiri VE, Palmer WC (2017) Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 19:2. https:\/\/doi.org\/10.1007\/s11894-017-0542-4","journal-title":"Curr Gastroenterol Rep"},{"key":"5729_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bpg.2015.01.002","volume":"29","author":"N Schweitzer","year":"2015","unstructured":"Schweitzer N, Vogel A (2015) Systemic therapy of cholangiocarcinoma: from chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol 29:345\u2013353. https:\/\/doi.org\/10.1016\/j.bpg.2015.01.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"5729_CR26","doi-asserted-by":"publisher","unstructured":"Pingpank JF, Libutti SK, Chang R et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465\u20133474. https:\/\/doi.org\/10.1200\/JCO.2005.00.927","DOI":"10.1200\/JCO.2005.00.927"},{"key":"5729_CR27","doi-asserted-by":"publisher","unstructured":"Forster MR, Rashid OM, Perez M, Choi J, Chaudhry T, Zager JS (2014) Percutaneous hepatic perfusion with melphalan for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 109:434\u2013439. https:\/\/doi.org\/10.1002\/jso.23501","DOI":"10.1002\/jso.23501"},{"key":"5729_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/jso.23474","volume":"109","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Zager JS (2014) Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol 109:383\u2013388. https:\/\/doi.org\/10.1002\/jso.23474","journal-title":"J Surg Oncol"},{"key":"5729_CR29","doi-asserted-by":"publisher","unstructured":"Abbott AM, Doepker MP, Kim Y et al (2017) Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol https:\/\/doi.org\/10.1097\/COC.0000000000000356","DOI":"10.1097\/COC.0000000000000356"},{"key":"5729_CR30","unstructured":"Melphalan for use with the hepatic delivery system treatment in patients with unresectable hepatocellular carcinoma or intra hepatic cholangiocarcinoma - full text view - ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415036?term=delcath&rank=3 . Accessed 11 Sep 2017"},{"key":"5729_CR31","unstructured":"Sequential Melphalan for use with hepatic delivery system treatment followed by Sorafenib in patients with unresectable HCC - full text view - ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02406508?term=delcath&rank= . Accessed 11 Sep 2017"},{"key":"5729_CR32","unstructured":"Percutaneous hepatic perfusion vs best alternative care in patients with hepatic-dominant ocular melanoma - full text view - ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02678572?term=delcath&rank=5 . Accessed 11 Sep 2017"},{"key":"5729_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","volume":"186","author":"TJ Vogl","year":"2014","unstructured":"Vogl TJ, Zangos S, Scholtz JE et al (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 186:937\u2013944. https:\/\/doi.org\/10.1055\/s-0034-1366081","journal-title":"Rofo"},{"key":"5729_CR34","unstructured":"Percutaneous hepatic perfusion vs. cisplatin\/gemcitabine in patients with intrahepatic cholangiocarcinoma - full text view - ClinicalTrials.gov . https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03086993 . Accessed 1 Sep 2017"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5729-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-018-5729-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5729-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T18:51:21Z","timestamp":1720637481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-018-5729-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["5729"],"URL":"https:\/\/doi.org\/10.1007\/s00330-018-5729-z","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"2 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Frank K. Wacker.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Steffen Marquardt reports a travel grant and lecture fees from Delcath Systems, Inc. during the conduct of the study.Martha M. Kirstein has no conflicts of interest related to the subject matter of the article.She received honoraria and travel grants from Shire, Novartis, Ipsen and Roche outside the submitted work.Roland Br\u00fcning has no conflicts of interest related to the subject matter of the article or outside the submitted work.Martin Zeile reports consulting and proctoring fees from Delcath systems, Inc.He reports consulting fees for Boston Scientific, Inc. outside the submitted work.Pier Francesco Ferrucci has no conflicts of interest related to the subject matter of the article or outside the submitted work.Warner Prevoo reports proctoring fees from Delcath systems, Inc.Boris Radeleff has no conflicts of interest related to the subject matter of the article or outside the submitted work.Herv\u00e9 Trillaud has no conflicts of interest related to the subject matter of the article or outside the submitted work.Lambros Tselikas has no conflicts of interest related to the subject matter of the article.He reports proctoring\/speaking fees for Cook Medical, BTG, GE Healthcare, Sirtex Medical, AMGEN and Pfizer.Emilio Vicente has no conflicts of interest related to the subject matter of the article or outside the submitted work.Philipp Wiggermann takes part in \"FOCUS Trial in Hepatic Dominant Ocular Melanoma - A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan\/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma\".He has no conflicts of interest outside the submitted work.Michael P. Manns has no conflicts of interest related to the subject matter of the article or outside the submitted work.Arndt Vogel reports personal fees and travel grants from Delcath Systems, Inc. He reports personal fees from Roche, Bayer, Lilly, Incyte, BMS, MSD and Amgen outside the submitted work.Frank K. Wacker reports a grant and personal\/proctoring fees from Delcath Systems, Inc. during the conduct of the study. He reports grants from Siemens Healthineers, Promedicus Ltd., BMBF, Forschungscampus STIMULATE, DFG, Rebirth-Cluster of Excellence and personal fees from Novartis Pharma GmbH outside the submitted work.After data collection of the current study, Hannover Medical School participated in the Phase 2 Clinical Trials in Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) (NCT 02415036).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Only three of the patients were included in a retrospective single-centre study: \"Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors\", published in <i>Journal of Research and Clinical Oncology<\/i>, including 29 patients with different primary and secondary liver malignancies.In our current study only patients with intrahepatic cholangiocarcinoma across nine different hospitals in Europe were included.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 Retrospective\u2022 Diagnostic\/prognostic study\u2022 Multicentre study","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}